Comparison of Different Oxygen Flow Rates During Preoxygenation Using High-Flow Nasal Oxygen
Launched by REGION STOCKHOLM · Dec 12, 2024
Trial Information
Current as of June 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different flow rates of high-flow nasal oxygen (HFNO) can improve a process called preoxygenation, which helps patients get enough oxygen before they undergo anesthesia for surgery. HFNO is a comfortable way to deliver oxygen, and it can be particularly useful during surgeries on the voice box because it allows for better visibility without needing a breathing tube. The researchers want to find out if higher flow rates of HFNO can make preoxygenation even more effective and allow patients to go without breathing for a longer time safely.
To participate in this trial, you need to be an adult between 18 and 84 years old, have a body mass index (BMI) under 35, and be scheduled for elective surgery. However, if you have certain health conditions, such as heart disease, severe asthma, or if you smoke, you may not be eligible. If you join the study, you can expect to receive HFNO at different flow rates and help researchers learn more about its benefits for patients like you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult, 18-84 years old
- • ASA 1-3
- • BMI \< 35
- • Planned for elective surgery
- Exclusion Criteria:
- • Cardiac disease (ischemic heart disease, heart failure (NYHA ≥2), ongoing arrhythmias, pulmonary hypertension)
- • Severe asthma, moderate to severe COPD
- • Pregnancy
- • Smokers or former smoker last finished 1 year before inclusion
- • Baseline oxygen saturation \< 95%
- • Nasal obstruction
- • Known or anticipated difficult airway
- • Patients with electrical active implants where lung impedance analysis is contraindicated
- • Not capable of understanding study information and signing a written consent
About Region Stockholm
Region Stockholm is a leading healthcare authority committed to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Stockholm collaborates with hospitals, research institutions, and industry partners to facilitate the development of new therapies and treatment protocols. With a focus on quality, safety, and ethical standards, the organization aims to enhance health outcomes for the diverse population of Stockholm and beyond, leveraging cutting-edge research to translate scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Solna, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported